Efficacy and safety of Bacteroides fragilis BF839 for pediatric autism spectrum disorder: a randomized clinical trial
文献类型：期刊论文
| 作者 | Lin, Chu-hui7; Zeng, Ting7; Lu, Cui-wei6; Li, De-yang5,6; Liu, Yi-ying4; Li, Bing-mei1,2,3; Chen, Sheng-qiang6; Deng, Yu-hong1,2,3,7 |
| 刊名 | FRONTIERS IN NUTRITION
 |
| 出版日期 | 2024-09-03 |
| 卷号 | 11页码:12 |
| 关键词 | autism spectrum disorder in children probiotics Bacteroides fragilis BF839 abnormal behavior gastrointestinal symptoms |
| ISSN号 | 2296-861X |
| DOI | 10.3389/fnut.2024.1447059 |
| 通讯作者 | Deng, Yu-hong(1376708863@qq.com) |
| 英文摘要 | Background: The clinical utility of Bacteroides fragilis in treating autism spectrum disorder (ASD) remains unclear. Therefore, this randomized, double-blind, placebo-controlled study aimed to explore the therapeutic effects and safety of B. fragilis BF839 in the treatment of pediatric ASD. Methods: We examined 60 children aged 2-10 years diagnosed with ASD, and participants received either BF839 powder (10 g/bar with >= 106 CFU/bar of viable bacteria, two bars/day) or placebo for 16 weeks. The primary outcomes was Autism Behavior Checklist (ABC) score. The secondary outcomes were Childhood Autism Rating Scale (CARS), Social Responsiveness Scale (SRS), Normal Development of Social Skills from Infants to Junior High School Children (S-M), Gastrointestinal Symptom Rating Scale (GSRS) scores, and fecal microbiome composition. Assessments were performed on day 0 and at weeks 8 and 16. Results: Compared with the placebo group, the BF839 group showed significant improvement in the ABC body and object use scores at week 16, which was more pronounced in children with ASD aged <4 years. Among children with a baseline CARS score >= 30, the BF839 group showed significant improvements at week 16 in the ABC total score, ABC body and object use score, CARS score, and GSRS score compared to the placebo group. Only two patients (6.67%) in the BF839 group experienced mild diarrhea. Compared with baseline and placebo group levels, the BF839 group showed a significant post-intervention increase in abundance of bifidobacteria and change in the metabolic function of neuroactive compounds encoded by intestinal microorganisms. Conclusion: BF839 significantly and safely improved abnormal behavior and gastrointestinal symptoms in children with ASD. |
| 收录类别 | SCI |
| WOS关键词 | SYMPTOM RATING-SCALE ; GUT MICROBIOTA ; CHILDREN ; POLYSACCHARIDE ; PROBIOTICS |
| 资助项目 | General Guidance Project of Guangzhou Health Science and Technology[BF839] |
| WOS研究方向 | Nutrition & Dietetics |
| 语种 | 英语 |
| WOS记录号 | WOS:001314650500001 |
| 出版者 | FRONTIERS MEDIA SA |
| 资助机构 | General Guidance Project of Guangzhou Health Science and Technology |
| 源URL | [http://ir.psych.ac.cn/handle/311026/48917]  |
| 专题 | 心理研究所_健康与遗传心理学研究室 |
| 通讯作者 | Deng, Yu-hong |
| 作者单位 | 1.Minist Educ China, Guangzhou, Peoples R China 2.Key Lab Neurogenet & Channelopathies Guangdong Pro, Guangzhou, Peoples R China 3.Guangzhou Med Univ, Affiliated Hosp 2, Inst Neurosci, Dept Neurol, Guangzhou, Peoples R China 4.Weierkang Specialist Outpatient Dept, Guangzhou, Peoples R China 5.Chinese Acad Sci, Inst Psychol, Beijing, Peoples R China 6.Guangzhou Med Univ, Med Adm Coll, Guangzhou, Peoples R China 7.Guangzhou Med Univ, Affiliated Hosp 2, Dept Clin Nutr, Guangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Lin, Chu-hui,Zeng, Ting,Lu, Cui-wei,et al. Efficacy and safety of Bacteroides fragilis BF839 for pediatric autism spectrum disorder: a randomized clinical trial[J]. FRONTIERS IN NUTRITION,2024,11:12. |
| APA | Lin, Chu-hui.,Zeng, Ting.,Lu, Cui-wei.,Li, De-yang.,Liu, Yi-ying.,...&Deng, Yu-hong.(2024).Efficacy and safety of Bacteroides fragilis BF839 for pediatric autism spectrum disorder: a randomized clinical trial.FRONTIERS IN NUTRITION,11,12. |
| MLA | Lin, Chu-hui,et al."Efficacy and safety of Bacteroides fragilis BF839 for pediatric autism spectrum disorder: a randomized clinical trial".FRONTIERS IN NUTRITION 11(2024):12. |
入库方式： OAI收割
来源：心理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。